Alliance

Quote






From the Lilly end - it is a seemingly stupid move because this stupid company has learned nothing about POTENTIAL drugs that we were SUPPOSED to get approved... Bydureon anyone?
To summarize, let's pay BI an obscene amount of money for drugs that may or may not come to market that we may or may not promote together, only after Lilly goes through yet another realignement....
 












Yeah, that part bothered me a little but. Big Bob stood on stage and said the days are over when we need others to help us sell our drugs. That was mid December. 30 days later we are in a big partnership with Lilly. Doesn't seem particularly transparent. He should have just left that part out.

Anonymous said:
Didn't BJ say we weren't going to enter into any more partnerships and BI would sell their own drugs? It doesn't make any sense on Lilly's end.
Click to expand...
 






Several reasons for this.

1. Belief that Lilly can actually SELL diabetes drugs (witness the disaster that Byetta was).

2. There are at least seven high ranking former Lilly people at BI now, including the franchise head for Diabets.

3. Mistaken belief they need SOV in the US to succeed. Its going to be more about contracting and clinical data than reps pounding the pavement. See Marty Carrol and his debacle at Merck for that lesson, which he didnt learn.

4. Belief that the value in this relationship is in fact not in the US but in the BRIC countries. BI and Lilly worked together on Cymbalta outside of the US.

Will this make more money for BI? No. Will it mitigate risk? Partly. Will it provide a CYA strategy for senior management. Definitely.
 












Top Bottom
Back
Quote